Abstract:Purpose While the phenomenon of R&D offshoring has become increasingly popular, scholars have mostly focused on R&D offshore outsourcing from the point of view of the client firms, who are often from an advanced country. By examining vendor firms, in this paper the authors shift the focus to the second party in the dyadic relationship of R&D offshore outsourcing. Specifically, the authors compare vendor firms with nonvendor firms from the same emerging economy and industry to look at whether vendor firms from emerging economies can improve their innovation performance by learning from their clients. The authors also look at the role of depth and breadth of existing technological capabilities of the vendor firm in its ability to improve its innovation performance. Design/methodology/approach This study is based on firm-level data from the Indian biopharmaceutical industry between 2005 and 2016. The authors use the Heckman two-stage model to control for self-selection by firms. The authors compare the innovation performance of vendor firms with nonvendor biopharmaceutical firms (group vs nongroup analysis) as well as innovation performance across vendor firms (within group comparison). Findings The authors find that, compared to nonvendor firms, R&D offshore outsourcing vendor firms from emerging economies have higher innovation performance. The authors argue that this higher innovation performance among vendor firms is due to learning from their clients. Among vendor firms, the authors find that the innovation gains are contingent upon the two factors of depth and breadth of the vendor firms' technological capabilities. Research limitations/implications This paper makes three contributions: First, the authors augment the nascent stream of research on innovation from emerging economy firms. The authors introduce a new mechanism for emerging economy firms to learn and upgrade their capabilities. Second, the authors contribute to the literature on global value chains, by showing that vendor firms are able to learn from their clients and upgrade their capabilities. Third, by examining the innovation by vendor firms, the authors contribute to the R&D offshore outsourcing, which has largely focused on the client. Practical implications The study findings have important implications for both clients and vendors. For client firms, the authors provide evidence that knowledge spillovers do happen, and R&D offshore outsourcing can turn vendors into potential competitors. This research helps firms from emerging economies by showing that becoming vendors for R&D offshore outsourcing is a viable option to learn from foreign firms and improve innovation performance. Going outside geographic boundaries may be a large hurdle for these resource-strapped, emerging economy firms. Providing offshore outsourcing services for narrow slices of R&D activities may be a starting point for these firms to upgrade their capabilities. Originality/value This paper is among the first to quantitatively study the innovation performance of vendor firms from emerging economies. The authors also contribute to the nascent literature on innovation in emerging economy firms by showing that providing R&D offshore outsourcing services to client firms from advanced countries can improve firms' innovation performance.

The growth and management of R&D outsourcing: evidence from UK pharmaceuticals

Innovation risks of outsourcing in pharmaceutical new product development

Does R&D offshore outsourcing improve innovation in vendor firms from emerging economies? A study of biopharmaceutical industry in India

Outsourcing R&D: a review, model, and research agenda

The Aftermath of Information Technology Outsourcing: an Empirical Study of Firm Performance Following Outsourcing Decisions

Trends and Innovations in Pharmaceutical R&D Outsourcing

Outsourcing of Regulatory Affairs Tasks in Pharmaceutical Companies—Why and What?

Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience

Evaluating outsourcing partners' capability: a case study from the pharmaceutical supply chain

Schrödinger's pipeline and the outsourcing of pharmaceutical innovation

Deriving and Assessing Strategic Priorities for Outsourcing Partner Selection in Pharmaceutical R&D: an Approach Using Analytic Hierarchy Process (AHP) Based on 34 Experts’ Responses From Korean Pharmaceutical Industry

Research and development spending and technical efficiency: evidence from biotechnology and pharmaceutical sector

Optimizing the R&D Process Using Spin-Outs: Case Studies from the Pharmaceutical Industry

Changing R&D models in research-based pharmaceutical companies

Outsourcing decision support: a survey of benefits, risks, and decision factors

Experience Report: an Industrial Experience Report on Test Outsourcing Practices

A robust R&D project portfolio optimization model for pharmaceutical contract research organizations

R&D, TECHNOLOGY TRANSFER AND PRODUCTIVITY IN THE INDIAN PHARMACEUTICAL INDUSTRY

A Study on ‘Why Outsourcing in Health Care’ by Friedman Two-way Analysis of Variance Method

Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline

Critical incidents of outsourcing processes in pharmaceutical supply chain: A mixed-methods approach